New Studies Confirm Shingles Vaccine Linked to Lower Dementia Risk

Got story updates? Submit your updates here. ›

Recent studies are turning conventional wisdom on its head, suggesting a powerful link between the shingles vaccine and a reduced risk of dementia. Researchers have leveraged 'natural experiments' - situations where vaccination policies created distinct groups of vaccinated and unvaccinated individuals - to uncover this connection. The results show a 3.5 percentage point reduction in dementia risk within seven years for those vaccinated against varicella-zoster virus (VZV), the virus that causes both chickenpox and shingles.

Why it matters

The emerging theory centers around the role of herpes viruses - including VZV - in neurodegenerative processes. Herpes viruses are known to establish lifelong latency in the nervous system, and their reactivation with age and declining immunity may contribute to chronic inflammation and neuronal damage, potentially accelerating the development of dementia. The shingles vaccine, by boosting immunity to VZV, may help control viral reactivation and mitigate these harmful effects.

The details

Researchers haven't relied on traditional clinical trials for this discovery. Instead, they've leveraged 'natural experiments' - situations where vaccination policies created distinct groups of vaccinated and unvaccinated individuals. For example, in Wales, individuals born shortly before and after a specific date in 2013 experienced different vaccination rates due to policy changes. This allowed researchers to compare dementia incidence between these groups, effectively mimicking a randomized controlled trial. The results were compelling, with the Welsh study showing a 3.5 percentage point reduction in dementia risk within seven years for those vaccinated against VZV. Similar findings emerged from Australia, with an 1.8 percentage point reduction in dementia diagnoses linked to vaccination eligibility. A more recent and methodologically robust study in Ontario, Canada, confirmed these findings, showing a 2 percentage point reduction in dementia risk.

• The Welsh study showed a 3.5 percentage point reduction in dementia risk within seven years for those vaccinated against varicella-zoster virus (VZV).
• The Australian study found an 1.8 percentage point reduction in dementia diagnoses linked to vaccination eligibility.
• The Ontario, Canada study confirmed a 2 percentage point reduction in dementia risk.

What’s next

The current research primarily focuses on the older, live-attenuated shingles vaccine, which is no longer widely available in the US and some European countries. However, promising data suggests the newer recombinant subunit vaccine may be even more effective. A study published in Nature Medicine showed the recombinant vaccine was associated with a lower risk of dementia compared to the live vaccine.